



The Impact Of Neonatal Hyperbilirubinemia Management On Neonatal Intensive care Unit Outcome In Zagazig University Hospital

*Thesis Submitted For Partial Fulfillment of PhD in Childhood
Studied (Child Health and Nutrition)
Department of Medical Studies for Children*

By

Wael Hassan Ahmed Hassan
Master Degree of Pediatrics, Zagazig University

Under Supervision of

Dr. Medhat Hassan Shehata

*Professor of Pediatrics
Faculty of Postgraduate Childhood Studies
Ain Shams University*

Dr. Rehab Abd Elkader Mahmoud

*Professor of Pediatrics
Faculty of Postgraduate Childhood Studies
Ain Shams University*

Dr. Abdelrazik El-Sheikh

*Professor of Pediatrics
Faculty of Medicine
Zagazig University*

Dr. Ayman Mohamed Nada

*Professor of Pediatrics
Faculty of Postgraduate Childhood Studies
Ain Shams University*

Dr. Amira Raafat Ghonemi

*Assistant Professor of Clinical Pathology
Faculty of Medicine
Zagazig University*

*Faculty of Postgraduate Childhood Studies
Ain Shams University*

2019

Acknowledgment

First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.

I'd like to express my respectful thanks and profound gratitude to *Prof. Medhat Hassan Shehata*, Professor of Pediatrics Institute of Postgraduate Childhood Studies Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.

I am also delighted to express my deepest gratitude and thanks to *Prof. Rehab Abd Elkader Mahmoud*, Professor of Pediatrics Institute of Postgraduate Childhood Studies Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

I am deeply thankful to *Prof. Abdelrazik El-Sheikh*, Professor of Pediatrics Faculty of Medicine Zagazig University, for his great help, active participation and guidance.

I wish to introduce my deep respect and thanks to *Prof. Ayman Mohamed Nada*, Professor of Pediatrics Institute of Postgraduate Childhood Studies Ain Shams University, for her kindness, supervision and cooperation in this work.

I wish to express my deepest thanks, gratitude and appreciation to *Prof. Amira Raafat Ghonemi*, Assistant Professor of Clinical Pathology Faculty of Medicine Zagazig University her meticulous supervision, kind guidance, valuable instructions and generous help.

Wael Hassan Ahmed Hassan

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ

فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

صدق الله العظيم
سورة النساء آية (١١٣)

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	vii
Introduction	1
Aim of the Study	5
Review of Literature	
▪ Bilirubin Metabolism	6
▪ Neonatal Jaundice	19
▪ Management of Neonatal Hyperbilirubinemia	55
Patients and Methods	88
Results	102
Discussion	135
Summary	156
Conclusion	159
Recommendations	160
References	162
Master Sheet	199
Appendices	228
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Drugs that cause significant displacement of bilirubin from albumin in vitro	33
Table (2):	Zones of cephalocaudal progression of jaundice in term infants in relation to serum bilirubin level.	39
Table (3):	Summary of Bind Score.	49
Table (4):	Clinical features of bilirubin encephalopathy.....	51
Table (5):	Approach for management of jaundiced newborn without hemolysis according to age.	55
Table (6):	Contraindication of phototherapy	81
Table (7):	Amiel-Tison neurological assessments (ATNA) score.	95
Table (8):	Summary of BIND score	96
Table (9):	Summarize all the developmental domains from birth to two years.....	98
Table (10):	Comparison between group I and group II regarding demographic data and anthropometric measurements.	104
Table (11):	Comparison between both group I and group II regarding Total and direct bilirubin level on admission and at discharge and the maximum total and direct bilirubin level reached during incubation.....	106
Table (12):	Comparison between group I and group II regarding Onset of maximum bilirubin level.....	108
Table (13):	Comparison between both group I and group II regarding CBC and other laboratory results.....	109
Table (14):	Comparison between both group I and group II regarding Blood grouping of the neonates.....	110
Table (15):	Comparison between both group I and group II regarding RH of the neonates.	111

List of Tables Cont...

Table No.	Title	Page No.
Table (16):	Comparison between group I and group II regarding Clinical manifestations suggestive of Bilirubin encephalopathy.....	116
Table (17):	Comparison between ATNA upon admission, at 3 months and 6 months old in group I.....	118
Table (18):	Comparison between ATNA upon admission, at 3 months and 6 months old in group II.	120
Table (19):	Correlations between ATNA and bilirubin level upon admission in both group I and group II.	122
Table (20):	Comparison between Mean levels of ATNA score upon admission, at 3 and 6 months in both groups.	126
Table (21):	Correlations between BIND score versus bilirubin level upon admission in group (I) and group (II).....	127
Table (22):	Follow-up mean levels of Bayley composite scores at 3m and 6m in group (I).	129
Table (23):	Follow-up mean levels of Bayley composite scores at 3m and 6m in group (II).....	130
Table (24):	Correlations between Bayley composite scores and bilirubin level upon admission in both group I and group II at 3 months and 6 months old.....	131
Table (25):	Comparison of Bayley composite scores between both groups at 3month and 6 months.	132
Table (26):	Comparison between group I and group II regarding duration of hospital stay.....	133

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Bilirubin production	6
Figure (2):	Bilirubin synthesis, transport, and excretion	7
Figure (3):	Metabolic Pathway of the Degradation of Heme and the Formation of Bilirubin	9
Figure (4):	Conversion of heme to biliverdin and then bilirubin	10
Figure (5):	Bilirubin transport and conjugation	12
Figure (6):	Show bilirubin metabolism	13
Figure (7):	Schematic representation of the steps involved in bilirubin (B) throughput in hepatocytes	15
Figure (8):	UDP-glucuronosyl transferases (UGT).....	16
Figure (9):	Neonatal jaundice	21
Figure (10):	A. Neonatal jaundice B. Identification is aided by pressure on the skin (jaundiced) C. No jaundice revealed by pressure	38
Figure (11):	Demonstrates zones of cephalocaudal progression of jaundice in term infants in relation to serum bilirubin level	39
Figure (12):	Transcutaneous bilirubin estimation	41
Figure (13):	Relationship of albumin-bound and unbound bilirubin levels in the vascular space to the entry, disposition and clearance from CNS	44
Figure (14):	Cell types and metabolic processes affected by bilirubin in the CNS	47
Figure (15):	Guidelines for use of phototherapy according to age	56
Figure (16):	Mechanism of phototherapy	58

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (17):	Normal Bilirubin Metabolism and Bilirubin Metabolism during Phototherapy.....	60
Figure (18):	Fluorescent blue lights phototherapy.....	61
Figure (19):	Fiberoptic blanket.....	62
Figure (20):	Neonate undergoing home phototherapy with fiberoptic blanket.....	63
Figure (21):	Bilibed device Home	64
Figure (22):	Infant undergoing home Bilibid phototherapy	64
Figure (23):	The (LED) device.....	65
Figure (24):	Intensive Phototherapy guidelines for all gestational ages	67
Figure (25):	Opaque eye shields	70
Figure (26):	Bilichex for evaluation of phototherapy in jaundiced babies	72
Figure (27):	Possible mechanisms of NNPT for allergic diseases.....	76
Figure (28):	Show TSB levels that need exchange transfusion.....	84
Figure (29):	Technique of exchange transfusion.....	86
Figure (30):	Algorithm for the management of jaundice in the newborn nursery.....	90
Figure (31):	Phototherapy pathway.....	91
Figure (32):	Exchange transfusion pathway	91
Figure (33):	Hour specific bilirubin nomogram.....	93
Figure (34):	Flow chart of both group I&II.	103
Figure (35):	Percentage of distribution of males and females in both groups.....	105
Figure (36):	Percentage of breast fed neonates in both groups.....	105
Figure (37):	Total bilirubin level on admission on both groups	107

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (38):	Maximum total bilirubin level on both groups	107
Figure (39):	Percentage of distribution of blood groups of the neonates.	110
Figure (40):	Percentage of distribution of Rh+ and Rh- in both groups.	111
Figure (41):	Age of studied neonates on admission in the two studied groups.....	112
Figure (42):	Onset of Jaundice (days) in group I	112
Figure (43):	Onset of Jaundice (days) in group II.....	113
Figure (44):	Phototherapy in group I.	113
Figure (45):	Phototherapy in group II.....	114
Figure (46):	Exchange transfusion in group I.	114
Figure (47):	Exchange transfusion in group II.....	115
Figure (48):	Comparison between group I and group II regarding high arched back.....	117
Figure (49):	Comparison between ATNA upon admission and at 3 months old in group I.	119
Figure (50):	Comparison between ATNA upon admission and at 3 months old in group II.....	121
Figure (51):	Correlation between bilirubin upon admission and ATNA upon admission in group (I).....	123
Figure (52):	Correlation between bilirubin upon admission and ATNA at 3 months of age in group (I).	123
Figure (53):	Correlation between bilirubin upon admission and ATNA at 6 months of age in group (I).	124
Figure (54):	Correlation between bilirubin upon admission and ATNA upon admission in group (II)	124

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (55):	Correlation between bilirubin upon admission and ATNA at 3 months of age in group (II).....	125
Figure (56):	Correlation between bilirubin upon admission and ATNA at 6 months of age in group (II).....	125
Figure (57):	Correlation between BIND score versus bilirubin level upon admission in group (I).	127
Figure (58):	Correlation between BIND score versus bilirubin level upon admission in group (II).....	128
Figure (59):	Comparison between group I and group II regarding duration of hospital stay.....	133
Figure (60):	Outcome in group I	134
Figure (61):	Outcome in group II.....	134

List of Abbreviations

Abb.	Full term
<i>AABR</i>	<i>Automated auditory brainstem response</i>
<i>AAP</i>	<i>American Academy of Pediatrics</i>
<i>ABE</i>	<i>Acute bilirubin encephalopathy</i>
<i>ATNA</i>	<i>Amiel-Tison Neurological Assessment</i>
<i>ATP</i>	<i>Adenosine triphosphate</i>
<i>BA</i>	<i>Biliary atresia</i>
<i>BAER</i>	<i>Brainstem auditory evoked response</i>
<i>BBS</i>	<i>Bronze baby syndrome</i>
<i>Bf</i>	<i>free bilirubin</i>
<i>BIND</i>	<i>Bilirubin-induced neurologic dysfunction</i>
<i>BR</i>	<i>Bilirubin</i>
<i>BV</i>	<i>Biliverdin</i>
<i>C/S</i>	<i>cesarean section</i>
<i>CBC</i>	<i>Complete blood picture</i>
<i>CBE</i>	<i>chronic bilirubin encephalopathy</i>
<i>CC</i>	<i>Choledochal cyst</i>
<i>cMOAT</i>	<i>Canalicular multispecific organic anion transporter</i>
<i>CN-I</i>	<i>Crigler-Najjar syndrome type I</i>
<i>CN-II</i>	<i>Crigler-Najjar syndrome type II</i>
<i>CO</i>	<i>Carbon monoxide</i>
<i>CPT</i>	<i>Conventional phototherapy</i>
<i>CPT</i>	<i>Conventional phototherapy</i>
<i>CRP</i>	<i>C-reactive protein</i>
<i>CRP</i>	<i>C-reactive protein</i>
<i>DAT</i>	<i>Direct Antiglobulin Test</i>
<i>DCT</i>	<i>Direct Coombs Test</i>
<i>ET</i>	<i>Exchange transfusion</i>
<i>FV</i>	<i>Femoral vein</i>
<i>G6PD</i>	<i>Glucose 6-phosphate dehydrogenase</i>
<i>GS</i>	<i>Gilbert's syndrome</i>
<i>GSTs</i>	<i>Glutathione S-transferases</i>
<i>Hb</i>	<i>Hemoglobin</i>

List of Abbreviations Cont...

Abb.	Full term
<i>HB</i>	<i>hyperbilirubinemia</i>
<i>Hct</i>	<i>Hematocrit</i>
<i>HD</i>	<i>Hemolytic disease</i>
<i>HIDA</i>	<i>Hepatobiliary iminodiacetic acid</i>
<i>IEM</i>	<i>Inborn errors of metabolism</i>
<i>IgG</i>	<i>Immunoglobulin G</i>
<i>IL</i>	<i>Interleukin</i>
<i>ILCOR- CoSTR</i> ..	<i>International Liaison Committee On Resuscitation- Consensus on Science with Treatment Recommendations</i>
<i>IQ</i>	<i>intellectual impairment</i>
<i>IVIG</i>	<i>Intravenous immune globulin</i>
<i>LEDs</i>	<i>Light-emitting diodes</i>
<i>LMICs</i>	<i>Low- and middle-income countries</i>
<i>MN</i>	<i>Melanocytic naevus</i>
<i>MRP2</i>	<i>Multi-drug resistance protein 2</i>
<i>NBLP</i>	<i>Neonatal blue-light phototherapy influences</i>
<i>NDD</i>	<i>Neurodevelopmental delay</i>
<i>NEC</i>	<i>Necrotising enterocolitis</i>
<i>NICE</i>	<i>National Institute for Health and Clinical Excellence</i>
<i>NICU</i>	<i>Neonatal intensive care unit</i>
<i>NNPT</i>	<i>Neonatal phototherapy</i>
<i>NNT</i>	<i>Number needed to treat</i>
<i>OATP</i>	<i>Organic-anion transporting polypeptides</i>
<i>PDA</i>	<i>Patent ductus arteriosus</i>
<i>PFIC</i>	<i>progressive familial intrahepatic cholestasis</i>
<i>PT</i>	<i>Phototherapy</i>
<i>Rh _ve</i>	<i>Rhesus negative</i>
<i>Rh+ve</i>	<i>Rhesus positive</i>
<i>RhD</i>	<i>Rhesus D</i>
<i>rh-EPO</i>	<i>Recombinant human erythropoietin</i>
<i>ROP</i>	<i>retinopathy of prematurity</i>

List of Abbreviations Cont...

Abb.	Full term
<i>SPSS</i>	<i>Statistical Package for the Social Science</i>
<i>TcB</i>	<i>Transcutaneous bilirubinometry</i>
<i>TNF</i>	<i>Tumor necrosis factor</i>
<i>TSB</i>	<i>Total serum bilirubin</i>
<i>UCB</i>	<i>unconjugated bilirubin</i>
<i>UDP</i>	<i>Uridine diphosphate</i>
<i>UGT</i>	<i>Uridine diphospho glucuronosyltransferase</i>
<i>UHWI</i>	<i>University Hospital of the West Indies</i>
<i>UV</i>	<i>Umbilical vein</i>
<i>UVC</i>	<i>Umbilical venous catheter</i>

ABSTRACT

Background: Neonatal hyperbilirubinemia, with consequent encephalopathy, remains a common cause of morbidity in developing countries so the challenge is early detection and treatment of neonatal hyperbilirubinemia to prevent adverse neurologic outcome.

Objective: The aim of this study was to assess the protocol of management of neonatal jaundice of Zagazig University hospital (according to Amercian Academy of Pediatrics guidelines) in comparison to the protocol Royal College University in UK according to outcome and feedback.

Patients and Methods: This is a prospective study including 213 neonates suffering from indirect hyperbilirubinemia admitted to the NICU of the Pediatric Hospital of Zagazig University Hospital between July 2013 and July 2014, However, parents of 8 newborns did not want to participate in the study, 5 newborns were excluded as they had exclusion criteria, and a total of 200 newborns with significant hyperbilirubinemia were finally included in the study during the study period.

Results: The comparison between ATNA upon admission, at 3M and 6 M old among all studied neonates. It shows that ATNA was significantly lower (optimal) at 3m compared to upon admission which means improvement in neurological performance, however non significant difference was detected between ATNA at 3m & 6m old in both groups. Higher statistically significant positive correlations was detected between bilirubin level upon admission and follow up versus ATNA score (intial, 3M and 6M) in both groups.

Conclusion: Neurodevelopmental assessment allows the detection of mild and moderate brain abnormalities and developmental delay.

Keywords: Neonatal hyperbilirubinemia, necrotising enterocolitis, intellectual impairment

INTRODUCTION

Neonatal jaundice is the yellow discoloration of the skin and eyes due to elevated bilirubin levels in the bloodstream of a newborn. Bilirubin is produced by the breakdown of red blood cells. Jaundiced infants are unable to process bilirubin at a normal rate or they have an abnormally high amount of bilirubin in their bloodstream, resulting in a buildup of the yellow colored bilirubin. That build up is called hyperbilirubinemia and is the cause of jaundice (*Hansen and Thor, 2016*).

Physiologic jaundice is also known as transient jaundice because it is the more common of the two types and is much less harmful. When infants are born, their livers are not fully developed. That immaturity makes it difficult for the liver to filter all of the bilirubin, the yellow-colored byproduct of red blood cell breakdown, from the bloodstream, resulting in infants with yellow tinged skin. Physiologic jaundice is the obstruction of the pathway for normal red blood cell breakdown (*Bradley and Arianna, 2017*).

Bilirubin levels with a deviation from the normal range and requiring intervention would be described as pathological jaundice. Appearance of jaundice within 24 h due to increase in serum bilirubin beyond 5 mg/dl/day, peak levels higher than the expected normal range, presence of clinical jaundice more than 2 weeks and conjugated bilirubin (dark urine staining the clothes) would be categorized under this type of jaundice (*Sana et al., 2016*).